Inventor · disambiguated record
David Bumcrot
Also filed as: BUMCROT DAVID · BUMCROT DAVID A · BUMCROT DAVID ANTON
52 granted patents·44 pending applications·1,037 citations·filing 1995–2025
98Inventor score
Files withALNYLAM PHARMACEUTICALS INC29EDITAS MEDICINE INC25CAMP4 THERAPEUTICS CORP15BUMCROT DAVID8HARVARD COLLEGE3
Top patents by PatentIndex Score
96 records- 0199US7749978B2Compositions and methods for inhibiting expression of Huntingtin geneALNYLAM PHARMACEUTICALS INC·Filed 2007·Granted Jul 6, 2010·113 cites·26 claims
- 0299US7718629B2Compositions and methods for inhibiting expression of Eg5 geneALNYLAM PHARMACEUTICALS INC·Filed 2007·Granted May 18, 2010·241 cites·33 claims
- 0399US7320965B2Compositions and methods for inhibiting expression of Huntingtin geneALNYLAM PHARMACEUTICALS INC·Filed 2006·Granted Jan 22, 2008·208 cites·8 claims
- 0498US8809516B2Therapeutic compositionsALNYLAM PHARMACEUTICALS INC·Filed 2012·Granted Aug 19, 2014·43 cites·22 claims
- 0597US8110674B2Therapeutic compositionsMANOHARAN MUTHIAH·Filed 2004·Granted Feb 7, 2012·81 cites·39 claims
- 0696US9879261B2Serpina1 siRNAs: compositions of matter and methods of treatmentALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Jan 30, 2018·10 cites·7 claims
- 0796US6576237B1Vertebrate tissue pattern-inducing proteins, and uses related theretoHARVARD COLLEGE·Filed 2000·Granted Jun 10, 2003·55 cites·31 claims
- 0895US10669544B2Therapeutic compositionsALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Jun 2, 2020·6 cites·20 claims
- 0995US10273477B2Therapeutic compositionsALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Apr 30, 2019·11 cites·20 claims
- 1095US10253312B2CRISPR/CAS-related methods and compositions for treating Leber's Congenital Amaurosis 10 (LCA10)EDITAS MEDICINE INC·Filed 2018·Granted Apr 9, 2019·13 cites·29 claims
- 1194US9938521B2CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10)EDITAS MEDICINE INC·Filed 2015·Granted Apr 10, 2018·12 cites·39 claims
- 1294US9708615B2Therapeutic compositionsALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Jul 18, 2017·10 cites·20 claims
- 1394US8124752B2Compositions and methods for inhibiting expression of the MYC geneBUMCROT DAVID·Filed 2007·Granted Feb 28, 2012·37 cites·8 claims
- 1494US6664075B2Nucleic acids encoding hedgehog proteinsHARVARD COLLEGE·Filed 2000·Granted Dec 16, 2003·42 cites·35 claims
- 1593US12234449B2CRISPR/Cas-related methods and compositions for treating Leber's congenital amaurosis 10 (LCA10)EDITAS MEDICINE INC·Filed 2022·Granted Feb 25, 2025·1 cites·17 claims
- 1692US11028388B2CRISPR/Cas-related methods and compositions for treating Usher syndrome and retinitis pigmentosaEDITAS MEDICINE INC·Filed 2015·Granted Jun 8, 2021·7 cites·22 claims
- 1791US11198876B2Compositions and methods for inhibiting expression of TMPRSS6 geneALNYLAM PHARMACEUTICALS INC·Filed 2018·Granted Dec 14, 2021·3 cites·23 claims
- 1891US9222091B2Therapeutic compositionsALNYLAM PHARMACEUTICALS INC·Filed 2014·Granted Dec 29, 2015·8 cites·18 claims
- 1990US11268086B2CRISPR/CAS-related methods and compositions for treating Leber's Congenital Amaurosis 10 (LCA10)EDITAS MEDICINE INC·Filed 2019·Granted Mar 8, 2022·3 cites·41 claims
- 2090US10935917B2Serpina1 siRNAs: compositions of matter and methods of treatmentALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Mar 2, 2021·2 cites·29 claims
- 2190US8754201B2Therapeutic compositionsMANOHARAN MUTHIAH·Filed 2010·Granted Jun 17, 2014·8 cites·26 claims
- 2290US8324368B2GNAQ targeted dsRNA compositions and methods for inhibiting expressionGOLLOB JARED·Filed 2009·Granted Dec 4, 2012·12 cites·36 claims
- 2390US6165747ANucleic acids encoding hedgehog proteinsHARVARD COLLEGE·Filed 1995·Granted Dec 26, 2000·69 cites·50 claims
- 2487US9175290B2Compositions and methods for inhibiting expression of TMPRSS6 geneBUMCROT DAVID·Filed 2012·Granted Nov 3, 2015·8 cites·37 claims
- 2586US11530408B2Therapeutic compositionsALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Dec 20, 2022·1 cites·20 claims
- 2685US11339437B2Compositions and methods for treating CEP290-associated diseaseEDITAS MEDICINE INC·Filed 2017·Granted May 24, 2022·3 cites·117 claims
- 2784US11542290B2Phenothiazine derivatives and uses thereofCAMP4 THERAPEUTICS CORP·Filed 2019·Granted Jan 3, 2023·2 cites·6 claims
- 2884US10100312B2Compositions and methods for inhibiting expression of TMPRSS6 geneALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Oct 16, 2018·3 cites·21 claims
- 2983US11001844B2CRISPR/Cas-related methods and compositions for treating herpes simplex virusEDITAS MEDICINE INC·Filed 2018·Granted May 11, 2021·2 cites·26 claims
- 3083US8445665B2Therapeutic compositionsMANOHARAN MUTHIAH·Filed 2010·Granted May 21, 2013·3 cites·14 claims
- 3183US2024255880A1Serpina1 sirnas: compositions of matter and methods of treatmentALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3283US2025270555A1Organic compositions to treat beta-catenin-related diseasesARROWHEAD PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3382US11242525B2CRISPR/CAS-related methods and compositions for treating sickle cell diseaseEDITAS MEDICINE INC·Filed 2015·Granted Feb 8, 2022·2 cites·28 claims
- 3482US8889644B2GNAQ targeted dsRNA compositions and methods for inhibiting expressionGOLLOB JARED·Filed 2012·Granted Nov 18, 2014·5 cites·29 claims
- 3581US8080532B2Compositions and methods for inhibiting expression of Huntingtin geneSAH DINAH WEN-YEE·Filed 2009·Granted Dec 20, 2011·2 cites·24 claims
- 3680US9006197B2Compositions and methods for inhibiting expression of Eg5 and VEGF genesBUMCROT DAVID·Filed 2012·Granted Apr 14, 2015·4 cites·27 claims
- 3779US2022155716A1Serpina1 sirnas: compositions of matter and methods of treatmentALNYLAM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3879US2025034193A1Phenothiazine derivatives and uses thereofCAMP4 THERAPEUTICS CORP·Filed 2024·Application pending·0 cites
- 3978US11141493B2Compositions and methods for treating CEP290-associated diseaseEDITAS MEDICINE INC·Filed 2018·Granted Oct 12, 2021·2 cites·35 claims
- 4077US12031133B2GNAQ targeted dsRNA compositions and methods for inhibiting expressionALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Jul 9, 2024·0 cites·16 claims
- 4177US9963700B2GNAQ targeted dsRNA compositions and methods for inhibiting expressionALNYLAM PHARMACEUTICALS INC·Filed 2016·Granted May 8, 2018·1 cites·24 claims
- 4277US2022251570A1Compositions and methods for inhibiting expression of tmprss6 geneALNYLAM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4376US12145963B2Phenothiazine derivatives and uses thereofCAMP4 THERAPEUTICS CORP·Filed 2022·Granted Nov 19, 2024·0 cites·1 claims
- 4476US2021041823A1Serpina1 sirnas: compositions of matter and methods of treatmentALNYLAM PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 4575US12319916B2Modulation of gene transcription using antisense oligonucleotides targeting regulatory RNAsCAMP4 THERAPEUTICS CORP·Filed 2024·Granted Jun 3, 2025·0 cites·15 claims
- 4675US11266655B2Methods and compositions for treating urea cycle disordersCAMP4 THERAPEUTICS CORP·Filed 2020·Granted Mar 8, 2022·1 cites·10 claims
- 4775US2024294917A1Crispr/cas-related methods and compositions for treating herpes simplex virus type 1 (hsv-1)EDITAS MEDICINE INC·Filed 2023·Application pending·0 cites
- 4872US8802639B2RNA interference modulators of hedgehog signaling and uses thereofBUMCROT DAVID A·Filed 2005·Granted Aug 12, 2014·3 cites·22 claims
- 4971US10954516B2GNAQ targeted dsRNA compositions and methods for inhibiting expressionALNYLAM PHARMACEUTICALS INC·Filed 2018·Granted Mar 23, 2021·0 cites·20 claims
- 5071US2022307083A1Assays and methods for determining activity of a therapeutic agent in a subjectALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
Showing the top 50 of 96 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when David Bumcrot files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →